Both in Biotechnology
Denali Therapeutics vs Recursion Pharmaceuticals
Over the past year DNLI returned +38.3% and RXRX returned −28.2%; their daily moves had a correlation of 0.44.
DNLI +38.3% RXRX −28.2%Growth of $1, one year, split-adjusted
| Metric | DNLI | RXRX |
|---|---|---|
| Price | $19.45 | $3.68 |
| Market cap | $3.11B | $2.20B |
| Today | +3.13% | −3.92% |
| 1 month | −2.3% | −23.0% |
| 6 months | +2.8% | +9.2% |
| Year to date | +17.8% | −10.0% |
| 1 year | +19.5% | −33.3% |
| Revenue growth (YoY) | — | +258.5% |
| Gross margin | 97.4% | 45.9% |
| Net margin | −3539.2% | −641.6% |
| P/E (TTM) | — | — |
| Price / sales | 862.7× | 32.2× |
| Net cash | $705.0M | $538.0M |
| Dividend yield | — | — |
| Volatility (60d) | 38.0% | 95.4% |
| Short % of float | 11.6% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).